科文斯现更名为Labcorp Drug Development

作为一家全球性公司,我们致力于为千百万人的福祉共同创新,持续为您带来更先进的医学突破。

了解详情

Preclinical, Clinical Trials & Diagnostics

Immuno-oncology & Oncology

联系我们

Your one source to achieve your next cancer breakthrough

More than half a million people with cancer will die this year; our mission is to be your one source to improve people's health and lives. 

From hundreds of preclinical tumor models and cell line assays to oncology clinical trials & post-market studies, we can help you get your next breakthrough cancer drug or precision medicine treatment to those who desperately need it.

临床试验

In the last five years, our expertise, insights and market impact have been demonstrated in excess of 975 oncology studies (300 in immuno-oncology) across nearly 19,000 sites in 83 countries with more than 104,000 oncology patients. 

Embrace a personalized medicine approach that targets therapies to specific subsets of patients and begins in the preclinical phase of drug development. 
如今,技术已成为患者支持计划的重中之重,但这并不是灵丹妙药。我们需要兼顾技术与人员和流程,以实现效率和风险的适当平衡。
Utilize biomarkers in clinical oncology development to provide key data for earlier decision making as well as patient and site selection

 

Co-develop a drug with an oncology companion diagnostics to help identify patients most likely to benefit from your next cancer breakthrough

临床前免疫治疗

业界已经从许多角度研究了免疫肿瘤学,因此需要鉴定、研发和完善能够概括最佳生物动力学以及关联和相关终点的模型。

精准医药和临床试验

要在用于临床试验的精准医药方面取得进展,就必须采用新颖的方法进行快速测试并为合适的个体提供合适的疗法。除了数十项后期免疫肿瘤学临床试验外,我们还为所有通过FDA批准的伴随诊断产品中的超过70%提供了支持。

Oncology Resources & Education

Oncology Events & Webinars

The Patient Journey in CAR T: Patient & Physician Perspectives
 

让我们开始对话

联系我们